Similar articles

• Paying for drug approvals--who's using whom?

  Avorn J. Avorn J. N Engl J Med. 2007 Apr 26;356(17):1697-700. doi: 10.1056/NEJMp078041. Epub 2007 Apr 13. N Engl J Med. 2007. PMID: 17435083 No abstract available.
• PDUFA reauthorization--drug safety's golden moment of opportunity?

  Hennessy S, Strom BL. Hennessy S, et al. N Engl J Med. 2007 Apr 26;356(17):1703-4. doi: 10.1056/NEJMp078048. Epub 2007 Apr 13. N Engl J Med. 2007. PMID: 17435082 No abstract available.
• Drug safety reform at the FDA--pendulum swing or systematic improvement?

  McClellan M. McClellan M. N Engl J Med. 2007 Apr 26;356(17):1700-2. doi: 10.1056/NEJMp078057. Epub 2007 Apr 13. N Engl J Med. 2007. PMID: 17435081 No abstract available.
• Regulatory considerations for determining postmarketing study commitments.

  Meyer RJ. Meyer RJ. Clin Pharmacol Ther. 2007 Aug;82(2):228-30. doi: 10.1038/sj.clpt.6100238. Epub 2007 May 30. Clin Pharmacol Ther. 2007. PMID: 17538552 Review.
• FDA Regulation of Prescription Drugs.

  Gassman AL, Nguyen CP, Joffe HV. Gassman AL, et al. N Engl J Med. 2017 Feb 16;376(7):674-682. doi: 10.1056/NEJMra1602972. N Engl J Med. 2017. PMID: 28199811 Review. No abstract available.